Why didn't (according to FDA) 35% of patients have their mutation status confirmed in the data submitted in the NDA? Will this issue be addressed in the validation of the diagnostic? 35% didn't have the mutation? That is sloppy scientific reporting, isn't it?
- Forums
- ASX - By Stock
- t315i mutation testing
Why didn't (according to FDA) 35% of patients have their...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CXS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online